Singapore markets closed
  • Straits Times Index

    3,166.27
    -55.25 (-1.72%)
     
  • Nikkei

    28,751.62
    -747.66 (-2.53%)
     
  • Hang Seng

    24,080.52
    -659.64 (-2.67%)
     
  • FTSE 100

    7,044.03
    -266.34 (-3.64%)
     
  • BTC-USD

    54,417.71
    -654.12 (-1.19%)
     
  • CMC Crypto 200

    1,365.60
    -89.82 (-6.17%)
     
  • S&P 500

    4,594.62
    -106.84 (-2.27%)
     
  • Dow

    34,899.34
    -905.04 (-2.53%)
     
  • Nasdaq

    15,491.66
    -353.57 (-2.23%)
     
  • Gold

    1,788.10
    +1.20 (+0.07%)
     
  • Crude Oil

    68.15
    -10.24 (-13.06%)
     
  • 10-Yr Bond

    1.4820
    -0.1630 (-9.91%)
     
  • FTSE Bursa Malaysia

    1,512.22
    -5.38 (-0.35%)
     
  • Jakarta Composite Index

    6,561.55
    -137.79 (-2.06%)
     
  • PSE Index

    7,278.44
    -90.83 (-1.23%)
     

Scott+Scott Attorneys at Law LLP Continues Investigation of Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, continues its investigation whether certain directors and officers of Regeneron Pharmaceuticals, Inc. ("Regeneron") (NASDAQ: REGN) breached their fiduciary duties to Regeneron and its shareholders. If you are a Regeneron shareholder, you are encouraged to contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@scott-scott.com.

Scott+Scott is investigating whether Regeneron’s board of directors or senior management failed to manage Regeneron in an acceptable manner, in breach of their fiduciary duties to Regeneron, and whether Regeneron has suffered damages as a result.

In January 2017, Regeneron received a subpoena from the U.S. Attorney’s Office for the District of Massachusetts regarding violations of federal anti-kickbacks statutes concerning use of patient-assistance funds to encourage doctors to prescribe certain of Regeneron’s drugs over less-expensive competitors.

In September 2019, Regeneron received a civil investigative demand from the U.S. Department of Justice pursuant to the federal False Claims Act investigating separate violations of federal anti-kickback statutes.

On June 24, 2020, federal prosecutors in Massachusetts filed suit against Regeneron, claiming violations of federal anti-kickback statutes.

What You Can Do

If you are a Regeneron shareholder, you may have legal claims against Regeneron’s directors and officers. If you wish to discuss this investigation, or have questions about this notice or your legal rights, please contact attorney Joe Pettigrew toll-free at (844) 818-6982 or jpettigrew@scott-scott.com.

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States. The firm represents pension funds, foundations, individuals, and other entities worldwide with offices in New York, London, Amsterdam, Connecticut, California, Ohio, and Virginia.

Attorney Advertising

View source version on businesswire.com: https://www.businesswire.com/news/home/20201202005853/en/

Contacts

Joe Pettigrew
Scott+Scott Attorneys at Law LLP
230 Park Avenue, 17th Floor, NY, New York 10169
(844) 818-6982
jpettigrew@scott-scott.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting